TI
EGRX

Turner Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Turner Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,500
Closed -$1.07M – 276
2016
Q4 		$1.07M Buy
+13,500
New +$981K 0.43% 92
2016
Q1 		– Sell
-26,500
Closed -$2.35M – 269
2015
Q4 		$2.35M Buy
+26,500
New +$2.09M 0.49% 68

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Turner Investments's EGRX Position: Q1 2017 in Review

Turner Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 13,500 shares — an estimated $1.07M sold.

Turner Investments first reported a position in EGRX in Q4 2015 and held it in 2 quarters. The position peaked at $2.35M in Q4 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Turner Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Turner Investments sold 13,500 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.07M.
  • Turner Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Turner Investments's Eagle Pharmaceuticals, Inc. position peaked at $2.35M in Q4 2015.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.